🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Tweetorial: Data from Drake Lab and others shows CSPC is immunologically different and not an ‘immune desert’ like CRPC. We interrogated CSPC metastases with single-cell RNA-seq (scRNA-seq), VIPER, and IF before and after tx w/ ADT +/- aPD-1 in a Phase 2 study. /1

Great fun collaborating with ⁦Rana McKay, MD, FASCO⁩ to bring this book to press. Special thanks to our authors for their insightful work! ⁦Kidney Cancer⁩ ⁦KidneyCAN⁩ ⁦Kidney Cancer Canada⁩ ⁦IKCC Kidney Cancer⁩ ⁦The James⁩ ⁦Ohio State Wexner Medical Center Urology Dept.⁩ ⁦The Ohio State University Wexner Medical Center⁩

I can't wait to read this paper on my way back from Nashville (Uromigos awesome meeting with Tom Powles Brian Rini, MD)==>IO/prostate cancer with good friend Chuck Drake and super star Jessica Hawley MD MS as 1st author: cell.com/cancer-cell/fu… •Protein-inferred activity clustering

Vote for Toni Choueiri, MD for the ASCO board. Toni is a visionary and experienced leader old-prod.asco.org/about-asco/asc…

What happens when we use a potent alpha emitter (225Ac) and a monoclonal antibody (J591) in #PSMA-TRT in castration-resistant prostate cancer? Led by Scott Tagawa, our new publication in @JCO describes safety & preliminary efficacy in dose escalation. A tweetorial! 1/9

Starting Now: Novel Therapies and Targets in Prostate Cancer. Moderated By: Matthew Cooperberg. Matt Cooperberg #DAVABroadmoorGU

📣New Trial Alert! Dr. Mark Stein Columbia Medicine discusses the biology and rationale for KLK2 and shares a brand new phase 1 trial with KLK2 x CD3 BsAb in advanced prostate cancer. classic.clinicaltrials.gov/ct2/show/NCT06… #DAVABroadmoorGU

A privilege to work with and learn from the late Filippo Dr. Filippo G. Giancotti and Dhiraj Kumar among many others. This work contributes to the great legacy of Filippo, one of the most rigorous cancer cell biologists in the world. nature.com/articles/s4301…

Thank you 🙏 UroToday.com Andrea Miyahira of PCF Science for discussing and highlighting our recent work published in Cancer Cell !! cell.com/cancer-cell/pd…

Congrats ZorkoNK for your new paper characterizing NK cell landscape in PCa, and the associated clinical and molecular features. Now it’s time for some NK-directed therapeutics in PCa. Thanks to PCF Science for funding this brilliant young investigator. nature.com/articles/s4139…

The 2024 #NYCProstateSummit is right around the corner. Mark your calendar and RSVP to join this free event featuring experts from Weill Cornell Medicine NewYork-Presbyterian Memorial Sloan Kettering Cancer Center and Columbia Medicine to hear the latest updates in #ProstateCancer care. prostatesummit.org

Patients and loved ones impacted by #ProstateCancer are invited to the 2024 #NYCProstateSummit to learn about key updates in genetic testing, integrative medicine, and the latest treatments. RSVP today to reserve your seat at this free event: prostatesummit.org

What if #immunotherapy 💉could impact #ProstateCancer as seen w/ #PSA 📉 & #PSMA🩻…but we’ve just been looking 👀 in the wrong place? Stop by @myesmo poster 🖼️ #1614 Sunday in the #ProstateCancer session #ESMO24

Fantastic effort by Lena Wirth and the whole team (Georgetown Lombardi Dana-Farber News Hoosier Cancer + many others) to understand some key (and targetable?) determinants of anti-PD-1 response/resistance in RCC Cancer Discovery Yale Cancer Center Yale Urology Yale Pathology Yale School of Medicine Yale Department of Immunobiology

We found out last night that the study section scheduled to review our R01 resubmission was cancelled 24hrs before the review. We spent months conducting experiments, writing and revising this proposal for prostate cancer research that represents 4 years of work. National Cancer Institute NIH

The latest collaboration led by the KaelinLab and #WuLab with David Braun, #SteveCarr, #DerinKeskin Eli Van Allen Dana-Farber Lank Center for Genitourinary Oncology Harvard Medical School Massachusetts Institute of Technology (MIT) DF/HCC in Cell: HIF-2, ERV, T cells, HLA, renal cell carcinoma, et al…. sciencedirect.com/science/articl…

Please save the Department of Defense 🇺🇸 Prostate Cancer Research Program! We need continued funding to keep fighting #ProstateCancer Senator Alex Padilla Adam Schiff Rep. Mike Levin UroToday.com PCF Science Howard Soule Andrea Miyahira Uromigos

From Challenges to Cures: Improving Outcomes in Patients With Renal Cell Carcinoma | JCO Oncology Practice ascopubs.org/doi/10.1200/OP…

Just in from ASCO #ASCO25 👉📢 Finally a T-cell engager in #prostatecancer mCRPC with minimal CRS syndrome (only grade 1, all outpatient dosing) and promising efficacy👇 Congrats #drbaldini Mark Stein and team Journal of Clinical Oncology OncoAlert UroToday.com PCF Science

📢 #ASCO25 | mCRPC Ph. I | KLK2×CD3 bispecific pasritamig: First-in-human (n = 174) shows PSA50 42.4%, median rPFS 6.8 m; G≥3 TRAEs 9.2%, no CRS > G1. by Dr. #CapucineBaldini from Gustave Roussy et al. Full abstract → [shorturl.at/meFe4] ASCO The ASCO Post Journal of Clinical Oncology